Fintech PR
Miami International Holdings Reports Trading Results for February 2024; MIAX Exchange Group YTD Options and Equities Volumes at Record Levels while MGEX Futures Volume Surges 30.3%
PRINCETON, N.J., March 7, 2024 /PRNewswire/ — Miami International Holdings, Inc. (MIH) today reported February 2024 trading results for its U.S. exchange subsidiaries – MIAX®, MIAX Pearl® and MIAX Emerald® (together, the MIAX Exchange Group), and Minneapolis Grain Exchange (MGEX™).
February 2024 and Year-to-Date Trading Volume and Market Share Highlights
- Total multi-listed options volume for the MIAX Exchange Group reached a monthly total of 145.3 million contracts, a 6.0% increase year-over-year (YoY) and representing an increase of 3.4% from January 2024. February 2024 market share reached 16.34%, a 2.7% decrease YoY. Total year-to-date (YTD) volume reached a record 285.8 million contracts, a 4.8% increase from the same period in 2023.
- MIAX Options reached a monthly volume of 58.3 million contracts, a 6.3% increase YoY and a 2.6% increase from January 2024. February 2024 market share reached 6.56%, a 2.4% decrease YoY. Total YTD volume reached a record 115.2 million contracts, a 4.9% increase from the same period in 2023.
- MIAX Emerald Options reached a monthly volume of 33.6 million contracts, a 22.7% increase YoY and a 6.0% increase from January 2024. February 2024 market share reached 3.78%, a 12.7% increase YoY.
- In U.S. equities, MIAX Pearl Equities™ reached a monthly volume of 4.1 billion shares, a 48.1% increase YoY and representing a market share of 1.73%, a 36.7% increase YoY. Total YTD volume reached a record 8.7 billion shares, a 73.8% increase from the same period in 2023.
- In U.S. futures, MGEX, a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO), reached a monthly volume of 329,921 contracts, a 30.3% increase YoY and representing a 49.9% increase from January 2024.
Additional MIAX Exchange Group and MGEX trading volume and market share information are included in the tables below.
|
Multi-Listed Options Trading Volume for MIAX Exchange Group, Current Month |
Year-to-Date Comparison |
||||||||
|
Multi-Listed Options |
Feb-24 |
Feb-23 |
% Chg |
Jan-24 |
% Chg |
Feb-24 |
Feb-23 |
% Chg |
|
|
Trading Days |
20 |
19 |
21 |
41 |
39 |
||||
|
U.S. Equity Options Industry |
888,779,369 |
816,156,925 |
8.9 % |
891,961,535 |
-0.4 % |
1,780,740,904 |
1,667,456,224 |
6.8 % |
|
|
MIAX Exchange Group |
145,254,160 |
137,080,466 |
6.0 % |
140,525,814 |
3.4 % |
285,779,974 |
272,642,891 |
4.8 % |
|
|
MIAX Options |
58,313,579 |
54,863,604 |
6.3 % |
56,855,169 |
2.6 % |
115,168,748 |
109,832,501 |
4.9 % |
|
|
MIAX Pearl |
53,312,809 |
54,820,051 |
-2.7 % |
51,931,661 |
2.7 % |
105,244,470 |
112,106,488 |
-6.1 % |
|
|
MIAX Emerald |
33,627,772 |
27,396,811 |
22.7 % |
31,738,984 |
6.0 % |
65,366,756 |
50,703,902 |
28.9 % |
|
|
Multi-Listed Options ADV |
Feb-24 |
Feb-23 |
% Chg |
Jan-24 |
% Chg |
Feb-24 |
Feb-23 |
% Chg |
|
|
U.S. Equity Options Industry |
44,438,968 |
42,955,628 |
3.5 % |
42,474,359 |
4.6 % |
43,432,705 |
42,755,288 |
1.6 % |
|
|
MIAX Exchange Group |
7,262,708 |
7,214,761 |
0.7 % |
6,691,705 |
8.5 % |
6,970,243 |
6,990,843 |
-0.3 % |
|
|
MIAX Options |
2,915,679 |
2,887,558 |
1.0 % |
2,707,389 |
7.7 % |
2,808,994 |
2,816,218 |
-0.3 % |
|
|
MIAX Pearl |
2,665,640 |
2,885,266 |
-7.6 % |
2,472,936 |
7.8 % |
2,566,938 |
2,874,525 |
-10.7 % |
|
|
MIAX Emerald |
1,681,389 |
1,441,937 |
16.6 % |
1,511,380 |
11.2 % |
1,594,311 |
1,300,100 |
22.6 % |
|
|
Multi-Listed Options Market Share for MIAX Exchange Group, Current Month |
Year-to-Date Comparison |
||||||||
|
Multi-Listed Options Market |
Feb-24 |
Feb-23 |
% Chg |
Jan-24 |
% Chg |
Feb-24 |
Feb-23 |
% Chg |
|
|
MIAX Exchange Group |
16.34 % |
16.80 % |
-2.7 % |
15.75 % |
3.7 % |
16.05 % |
16.35 % |
-1.8 % |
|
|
MIAX Options |
6.56 % |
6.72 % |
-2.4 % |
6.37 % |
2.9 % |
6.47 % |
6.59 % |
-1.8 % |
|
|
MIAX Pearl |
6.00 % |
6.72 % |
-10.7 % |
5.82 % |
3.0 % |
5.91 % |
6.72 % |
-12.1 % |
|
|
MIAX Emerald |
3.78 % |
3.36 % |
12.7 % |
3.56 % |
6.3 % |
3.67 % |
3.04 % |
20.7 % |
|
|
Equities Trading Volume for MIAX Pearl Equities, Current Month |
Year-to-Date Comparison |
|||||||
|
Equities Shares (millions) |
Feb-24 |
Feb-23 |
% Chg |
Jan-24 |
% Chg |
Feb-24 |
Feb-23 |
% Chg |
|
Trading Days |
20 |
19 |
21 |
41 |
39 |
|||
|
U.S. Equities Industry |
234,704 |
216,694 |
8.3 % |
242,622 |
-3.3 % |
477,325 |
443,244 |
7.7 % |
|
MIAX Pearl Volume |
4,062 |
2,743 |
48.1 % |
4,604 |
-11.8 % |
8,667 |
4,986 |
73.8 % |
|
MIAX Pearl ADV |
203 |
144 |
40.7 % |
219 |
-7.4 % |
211 |
128 |
65.3 % |
|
MIAX Pearl Market Share |
1.73 % |
1.27 % |
36.7 % |
1.90 % |
-8.8 % |
1.82 % |
1.12 % |
61.4 % |
|
Futures & Options Trading Volume and Open |
Year-to-Date Comparison |
|||||||
|
Futures Contracts |
Feb-24 |
Feb-23 |
% Chg |
Jan-24 |
% Chg |
Feb-24 |
Feb-23 |
% Chg |
|
Trading Days |
20 |
19 |
21 |
41 |
39 |
|||
|
MGEX Total |
329,921 |
253,274 |
30.3 % |
220,026 |
49.9 % |
549,947 |
418,874 |
31.3 % |
|
MGEX Average Daily Volume |
16,496 |
13,330 |
23.7 % |
10,477 |
57.4 % |
13,413 |
10,740 |
24.9 % |
|
MGEX Open Interest |
71,095 |
57,070 |
24.6 % |
80,674 |
-11.9 % |
|||
About MIAX
MIAX’s parent holding company, Miami International Holdings, Inc., owns Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEX™), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX) and Dorman Trading, LLC (Dorman Trading).
MIAX, MIAX Pearl and MIAX Emerald are national securities exchanges registered with the Securities and Exchange Commission that are enabled by MIAX’s in-house built, proprietary technology. MIAX offers trading of options on all three exchanges as well as cash equities through MIAX Pearl Equities™. The MIAX trading platform was built to meet the high-performance quoting demands of the U.S. options trading industry and is differentiated by throughput, latency, reliability and wire-order determinism. MIAX also serves as the exclusive exchange venue for cash-settled options on the SPIKES® Volatility Index (Ticker: SPIKE), a measure of the expected 30-day volatility in the SPDR® S&P 500® ETF (SPY).
MGEX is a registered exchange with the Commodity Futures Trading Commission (CFTC) and offers trading in a variety of products including Hard Red Spring Wheat Futures. MGEX is a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO) under the CFTC, providing DCM and DCO services in an array of asset classes.
LedgerX is a CFTC regulated exchange and clearinghouse and is registered as a Designated Contract Market (DCM), Derivatives Clearing Organization (DCO) and Swap Execution Facility (SEF) with the CFTC.
BSX is a fully electronic, vertically integrated international securities market headquartered in Bermuda and organized in 1971. BSX specializes in the listing and trading of capital market instruments such as equities, debt issues, funds, hedge funds, derivative warrants, and insurance linked securities.
Dorman Trading is a full-service Futures Commission Merchant registered with the CFTC.
MIAX’s executive offices and National Operations Center are located in Princeton, N.J., with additional U.S. offices located in Chicago, IL and Miami, FL. MGEX offices are located in Minneapolis, MN. LedgerX offices are located in Princeton, N.J. BSX offices are located in Hamilton, Bermuda. Dorman Trading offices are located in Chicago, IL.
To learn more about MIAX visit www.miaxglobal.com.
To learn more about MGEX visit www.miaxglobal.com/mgex.
To learn more about LedgerX visit www.ledgerx.com.
To learn more about BSX visit www.bsx.com.
To learn more about Dorman Trading visit www.dormantrading.com.
Disclaimer and Cautionary Note Regarding Forward-Looking Statements
The press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities of Miami International Holdings, Inc. (together with its subsidiaries, the Company), and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer; solicitation or sale would be unlawful. This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
All third-party trademarks (including logos and icons) referenced by the Company remain the property of their respective owners. Unless specifically identified as such, the Company’s use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between the owners of these trademarks and the Company. Any references by the Company to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
Media Contact:
Andy Nybo, SVP, Chief Communications Officer
(609) 955-2091
[email protected]
Logo – https://mma.prnewswire.com/media/1396492/4582185/MIAX_Logo.jpg
View original content:
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
Money20/20 Asia 2024: Days Two Roundup
-
Latest News3 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News6 days ago
Stripe Unveils Unbundled Payments Strategy in Fintech Pivot
-
Latest News3 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News3 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News6 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News7 days ago
Chubb Report: Damage During Home Renovations and from Extreme Weather are Top Concerns of U.K. High Earners
-
Latest News7 days ago
Payflows Emerges from Stealth with €25 Million Series A Funding Round